Risk of prostate cancer in relation to polymorphisms of metabolic genes

被引:25
作者
Chen, C [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
关键词
D O I
10.1093/oxfordjournals.epirev.a000793
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The study of associations between genetic polymorphisms of metabolic enzymes and prostate cancer risk can provide insight into the potential etiologic role of xenobiotics in prostate cancer development. To date there is little evidence that the incidence of prostate cancer is influenced by any of the genetic polymorphisms described above. However, the number of subjects studied generally has been small, so it would be premature to conclude that the substances metabolized by enzymes encoded by these candidate genes are not of carcinogenic importance, or to conclude that the polymorphisms of these genes do not play a role in prostate cancer susceptibility. Larger-scale studies of these and other genes, such as genes that repair cellular damage and regulate cell growth, are needed. Since gene-gene and gene-environment interactions may contribute to cancer risk, it would be desirable to conduct studies in which both biomarkers (or other measures) of exposure and polymorphisms of multiple genes are examined.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 86 条
  • [21] Susceptibility to endometrial cancer: Influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci
    Esteller, M
    Garcia, A
    MartinezPalones, JM
    Xercavins, J
    Reventos, J
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1385 - 1388
  • [22] Febbo PG, 1998, CANCER EPIDEM BIOMAR, V7, P1075
  • [23] FOEST U, 1991, Human and Experimental Toxicology, V10, P25
  • [24] N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development
    Fukutome, K
    Watanabe, M
    Shiraishi, T
    Murata, M
    Uemura, H
    Kubota, Y
    Kawamura, J
    Ito, H
    Yatani, R
    [J]. CANCER LETTERS, 1999, 136 (01) : 83 - 87
  • [25] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
    Goldstein, JA
    Ishizaki, T
    Chiba, K
    deMorais, SMF
    Bell, D
    Krahn, PM
    Evans, DAP
    [J]. PHARMACOGENETICS, 1997, 7 (01): : 59 - 64
  • [26] GRANT DM, 1991, MOL PHARMACOL, V39, P184
  • [27] Human acetyltransferase polymorphisms
    Grant, DM
    Hughes, NC
    Janezic, SA
    Goodfellow, GH
    Chen, HJ
    Gaedigk, A
    Yu, VL
    Grewal, R
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 376 (1-2) : 61 - 70
  • [28] Guengerich FP, 1995, PHARMACOGENETICS, V5, P103
  • [29] Cytochrome P-450 3A4: Regulation and role in drug metabolism
    Guengrich, FP
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 1 - 17
  • [30] EXPRESSION OF MODIFIED HUMAN CYTOCHROME-P450-1A1 IN ESCHERICHIA-COLI - EFFECTS OF 5' SUBSTITUTION, STABILIZATION, PURIFICATION, SPECTRAL CHARACTERIZATION, AND CATALYTIC PROPERTIES
    GUO, ZY
    GILLAM, EMJ
    OHMORI, S
    TUKEY, RH
    GUENGERICH, FP
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 312 (02) : 436 - 446